Abstract
Atrial fibrillation (AF) is the most common chronic arrhythmia and a source of significant morbidity and mortality. Previous studies have identified numerous risk factors for the development of AF, including hypertension, diabetes mellitus and heart failure, which have known pathophysiologic links with inflammatory processes. The importance of inflammation in inducing and perpetuating AF has been highlighted not only by experimental, epidemiological and cohort observational studies, but also by clinical trials providing evidence that inflammatory pathways are involved in AF pathogenesis. Local and systemic measurements of biomarkers and inflammatory mediators, as well as atrial biopsy studies have also given insight as to the purported relationship between this arrhythmia and inflammation. However, the link between inflammation and AF is still poorly defined and several issues remain unresolved. The present review offers an overview of existing evidence supporting the “inflammatory” hypothesis for AF pathophysiology and potential therapeutic means for counteracting this “foul interplay” between arrhythmia and inflammation.
Keywords: Anti-inflammatory, atrial fibrillation, CRP, inflammation, interleukin.
Medicinal Chemistry
Title:Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Volume: 10 Issue: 7
Author(s): Georgios Giannopoulos, Michael W. Cleman and Spyridon Deftereos
Affiliation:
Keywords: Anti-inflammatory, atrial fibrillation, CRP, inflammation, interleukin.
Abstract: Atrial fibrillation (AF) is the most common chronic arrhythmia and a source of significant morbidity and mortality. Previous studies have identified numerous risk factors for the development of AF, including hypertension, diabetes mellitus and heart failure, which have known pathophysiologic links with inflammatory processes. The importance of inflammation in inducing and perpetuating AF has been highlighted not only by experimental, epidemiological and cohort observational studies, but also by clinical trials providing evidence that inflammatory pathways are involved in AF pathogenesis. Local and systemic measurements of biomarkers and inflammatory mediators, as well as atrial biopsy studies have also given insight as to the purported relationship between this arrhythmia and inflammation. However, the link between inflammation and AF is still poorly defined and several issues remain unresolved. The present review offers an overview of existing evidence supporting the “inflammatory” hypothesis for AF pathophysiology and potential therapeutic means for counteracting this “foul interplay” between arrhythmia and inflammation.
Export Options
About this article
Cite this article as:
Giannopoulos Georgios, Cleman W. Michael and Deftereos Spyridon, Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart, Medicinal Chemistry 2014; 10 (7) . https://dx.doi.org/10.2174/1573406410666140318110100
DOI https://dx.doi.org/10.2174/1573406410666140318110100 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE-5 Inhibitors: Clinical Points
Current Drug Targets Neutrophil F-actin Dynamics in Familial Mediterranean Fever: The Unequal Effect of Colchicine on Activated Neutrophils
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Editorial (Epigenetics: A Paradigm Shift in Understanding Alzheimer’s Disease)
Current Alzheimer Research Advances in Antithrombotic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?
Current Vascular Pharmacology Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Epsilon Waves as an Extreme Form of Depolarization Delay: Focusing on the Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Current Cardiology Reviews Diabetic Cardiomyopathy and its Prevention by Metallothionein: Experimental Evidence, Possible Mechanisms and Clinical Implications
Current Medicinal Chemistry